Novartis

Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra
Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra
Fierce Pharma
Novartis
COVID-19
Pfizer
BioNTech
CureVac
Roche
API
Actemra
Flag link:
Genentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair
Genentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair
BioSpace
Genentech
Novartis
FDA
Xolair
allergies
Flag link:
Novartis expands in radio-oncology again with $1.3bn Artios alliance
Novartis expands in radio-oncology again with $1.3bn Artios alliance
Pharmaforum
Novartis
radioligands
Artios Pharma
precision medicine
radio-oncology
Flag link:
Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds
Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds
Endpoints
Novartis
radioligands
iTheranostics
Flag link:
Novartis pushes back on chairman's 'inaccurate and inconsistent' comments undermining bribery settlement
Novartis pushes back on chairman's 'inaccurate and inconsistent' comments undermining bribery settlement
Endpoints
Novartis
bribery
physicians
DOJ
kickbacks
Flag link:
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand
Fierce Pharma
Novartis
gene therapy
layoffs
Colorado
drug manufacturing
Flag link:
Novartis' radioligand hits goal in phase 3 prostate cancer trial
Novartis' radioligand hits goal in phase 3 prostate cancer trial
Fierce Biotech
Novartis
radioligand
177Lu-MSMA-617
prostate cancer
clinical trials
Flag link:
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
Fierce Pharma
JNJ
Ponvory
Novartis
Bristol-Myers Squibb
MS
multiple sclerosis
Flag link:
Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take
Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take
Endpoints
MPM Capital
radiopharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders
Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders
Endpoints
Eli Lilly
Novartis
protein degradation
Amphista
Flag link:
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
BioSpace
Novartis
canakinumab
clinical trials
metastatic non-small cell lung cancer
Flag link:
Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Novartis sues FDA over its stance on Sanofi blockbuster’s exclusivity
Endpoints
Novartis
generics
Sandoz
FDA
Aubagio
multiple sclerosis
MS
Flag link:
Setback for Novartis drug in advanced lung cancer trial
Setback for Novartis drug in advanced lung cancer trial
Biopharma Reporter
Novartis
clinical trials
canakinumab
metastatic non-small cell lung cancer
Flag link:
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Fierce Pharma
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Novartis
Kymriah
Flag link:
Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda
Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda
Fierce Pharma
Pfizer
Lorbrena
non-small cell lung cancer
Novartis
Roche
Takeda
Flag link:
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Pharmaforum
dry eye disease
Novartis
Xiidra
Sylentis
Azura Ophthalmics
Flag link:
Novartis pairs up with CureVac to help drive Covid-19 shot production but may miss the show in the US, EU
Novartis pairs up with CureVac to help drive Covid-19 shot production but may miss the show in the US, EU
Endpoints
Novartis
vaccines
CureVac
COVID-19
drug manufacturing
Flag link:
Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use
Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use
Fierce Pharma
Novartis
Kesimpta
MS
multiple sclerosis
Flag link:
Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales
Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales
Fierce Pharma
Novartis
executive pay
Vas Narasimhan
Pharma CEOs
pandemic
COVID-19
Flag link:
A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal
A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal
Endpoints
BieGene
Novartis
Boston Immune Technologies
TNFR2
Flag link:

Pages